Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in life-threatening therapy-resistant progressive interstitial pneumonitis
2013-005269-37Phase 2Active
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in interstitial pneumonia and Immuno-inflammatory lung disease, sponsored by St. Antonius Ziekenhuis. Primary endpoints: Pulmonary function tests and Quality of life. Started Jul 2014; status: active.
02
Drugs
rituximab
03
Conditions
interstitial pneumoniaImmuno-inflammatory lung disease
Beyond the preview
Go deeper on 2013-005269-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005269-37.